Superworth

Gyre Therapeutics price to book ratio GYRE

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
6.0×
10-year median
1.3×
Against its 10-year history
70th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.2× to 23.7×
Peer median
2.3×

Gyre Therapeutics' price to book ratio is 6.0× as of Oct 23, 2026.

That is above its ten-year median of 1.3×, higher than on 70% of days in the last ten years.

Over that time it ranged from 0.2× in Sep 2022 to 23.7× in Nov 2024.

The median for 10 large drugmakers of a similar size is 2.3×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far6.0×5.5×7.8×
20256.9×6.7×17.9×
202418.4×8.3×23.7×
202318.5×0.2×21.4×
20220.6×0.2×2.2×
20210.5×0.5×2.5×
20201.5×0.7×1.5×
20191.0×0.7×1.1×
20180.7×0.6×11.2×
20172.4×0.2×2.4×
20160.4×0.4×0.9×
20151.0×0.2×1.1×
20140.8×0.7×1.3×
20130.9×0.8×1.3×
20120.8×0.7×1.4×
20111.0×1.0×3.5×

Against its peers

Companies in Drug Manufacturers - General nearest Gyre Therapeutics' size, closest first, today.

CompanyPrice to book ratio
GYREGyre Therapeutics6.0×
CRMDCorMedix1.3×
ZVRAZevra Therapeutics2.7×
IRWDIronwood Pharmaceuticalsn/m
COLLCollegium Pharmaceutical2.4×
PBYIPuma Biotechnology4.1×
ABUSArbutus Biopharma3.2×
ARVNArvinas0.8×
AMPHAmphastar Pharmaceuticals1.4×
OMEROmerosn/m
PCRXPacira BioSciences2.2×
Peer median2.3×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Gyre Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.